CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

In a Jan. 13th installation of the Stanford Cancer Institute’s “Breakthroughs in Cancer” lecture series, Lawrence Fong ...

In recent years, cancer immunotherapy has transformed the treatment landscape for a wide range of malignancies, offering ...

Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study. NECTIN4 RNA expression and clinical outcomes ...

Tumor immunotherapy has rapidly emerged as a cornerstone in oncology, revolutionizing the treatment landscape for patients with advanced malignancies.

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

A 2024 U.S. national survey reported that 11.8% of males and 7.6% of females ages 12 and older met the criteria for Alcohol ...

Subcutaneous allergen-specific immunotherapy has long been used in allergic rhinitis and/or asthma and has been recognized to be efficacious. However, owing to the inconvenience of injection and the ...

Patients with certain types of cancers who consume sucralose, found in the artificial sweetener Splenda, respond worse to immunotherapy compared with those who don’t, researchers report July 30 in ...

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell ...

BriaCell (BCTX) Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, ...